Armistice Capital’s Enveric Biosciences ENVB Stock Holding History

Armistice Capital’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,517	Closed	-$355K	–	361
2023 Q4	$355K	Buy	+1,517	New	+$466K	﹤0.01%	212

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Armistice Capital's ENVB Position: Q1 2024 in Review

Armistice Capital sold out of Enveric Biosciences (ENVB) in Q1 2024, closing a stake of 1,517 shares — an estimated $355K sold.

Armistice Capital first reported a position in ENVB in Q4 2023 and held it in 1 quarter. The position peaked at $355K in Q4 2023. 15 funds tracked by Wall St. Rank hold ENVB as of Q1 2024.

Armistice Capital reported no remaining Enveric Biosciences position as of Q1 2024 after selling out during the quarter.
Armistice Capital sold 1,517 Enveric Biosciences shares in Q1 2024, an estimated $355K.
Armistice Capital first reported a position in Enveric Biosciences in Q4 2023 and held it in 1 quarter.
Armistice Capital's Enveric Biosciences position peaked at $355K in Q4 2023.
15 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.